Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.47 |
| ▸ | HTR2B | P41595 | 4/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263594 | 1.00 | MCHR1 (0.60) | MCHR1ADRA2AHTR2BHRH1ADRA1A | |
| SCHEMBL4255611 | 0.91 | MCHR1 (0.55) | MCHR1ADRA2AHTR2BHRH1ADRA1A | |
| SCHEMBL4255612 | 0.91 | MCHR1 (0.55) | MCHR1ADRA2AHTR2BHRH1ADRA1A | |
| SCHEMBL4264899 | 0.91 | MCHR1 (0.72) | MCHR1ADRA2AHTR2BHRH1ADRA1A | |
| SCHEMBL4264896 | 0.91 | MCHR1 (0.72) | MCHR1ADRA2AHTR2BHRH1ADRA1A | |
| SCHEMBL4263539 | 0.90 | MCHR1 (0.60) | MCHR1ADRA2AHTR2BHRH1ADRA1A | |
| SCHEMBL4263541 | 0.90 | MCHR1 (0.60) | MCHR1ADRA2AHTR2BHRH1ADRA1A | |
| SCHEMBL4262355 | 0.88 | MCHR1 (0.52) | MCHR1ADRA2AHTR2BHRH1ADRA1A | |
| SCHEMBL4262351 | 0.88 | MCHR1 (0.52) | MCHR1ADRA2AHTR2BHRH1ADRA1A | |
| SCHEMBL4258625 | 0.88 | MCHR1 (0.56) | MCHR1ADRA2AHTR2BHRH1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | MCHR1 3/4885ADRA2A 178/4885HTR2B 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.